Funding for this research was provided by:
Received: 14 June 2021
Accepted: 12 October 2021
First Online: 29 October 2021
: C-axSpAnd was approved by institutional review boards and independent ethics committees at participating sites and was conducted in accordance with local regulations and the International Conference on Harmonization Good Clinical Practice requirements, based on the Declaration of Helsinki. All patients provided written informed consent to participate.
: Not applicable.
: <i>WPM</i>: honoraria/consulting fees from AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma; research grants from AbbVie and Pfizer; educational grants from AbbVie, Janssen, Novartis and Pfizer; Chief Medical Officer for CARE Arthritis Limited. <i>TK</i>, <i>SEA</i>, <i>BH</i> and <i>LB</i>: employees of UCB Pharma; own stock awards in UCB Pharma. <i>MR</i>: speakers bureau for AbbVie, Eli Lilly, Novartis and UCB Pharma; consultant of AbbVie, Celgene, Eli Lilly, Janssen, Novartis and UCB Pharma.